Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Axsome Therapeutics, Inc. AXSM
$78.50
+$0.53 (0.68%)
На 18:00, 12 мая 2023
+3.18%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
3406418424.00000000
-
week52high
82.85
-
week52low
20.63
-
Revenue
50037106
-
P/E TTM
-16
-
Beta
1.89896100
-
EPS
-4.63000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:00
Описание компании
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Equal-Weight | 30 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 23 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 22 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 10 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 08 июл 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 30 сент 2022 г. |
| Jefferies | Buy | Buy | 30 сент 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 14 окт 2022 г. |
| Guggenheim | Buy | Buy | 14 окт 2022 г. |
| Loop Capital | Buy | 01 ноя 2022 г. | |
| Guggenheim | Buy | Buy | 11 ноя 2022 г. |
| Mizuho | Buy | Buy | 09 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 08 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 29 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 29 ноя 2022 г. |
| Piper Sandler | Neutral | 05 янв 2023 г. | |
| BTIG | Buy | Buy | 23 дек 2022 г. |
| Mizuho | Buy | Buy | 30 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Coleman Mark | D | 0 | 17501 | 03 янв 2023 г. |
| Coleman Mark | A | 25097 | 17501 | 03 янв 2023 г. |
| Coleman Mark | A | 16976 | 16976 | 03 июн 2022 г. |
| JEFFS ROGER | A | 16976 | 16976 | 03 июн 2022 г. |
| Saad Mark E | A | 16976 | 16976 | 03 июн 2022 г. |
| Coleman Mark | D | 17501 | 3496 | 15 мар 2022 г. |
| Coleman Mark | A | 7596 | 3496 | 15 мар 2022 г. |
| Saad Mark E | A | 2337 | 2337 | 04 мар 2022 г. |
| JEFFS ROGER | A | 2347 | 2347 | 04 мар 2022 г. |
| Coleman Mark | A | 2798 | 2798 | 04 мар 2022 г. |
Новостная лента
2 Magnificent Growth Stocks You Can Buy With $150 Right Now
The Motley Fool
10 мая 2023 г. в 05:11
Investing in growth stocks can be far less risky if you make smaller, more frequent purchases of your favorite companies. Axsome Therapeutics is a commercial-stage drugmaker that recently launched a new treatment for depression, one of the most commonly diagnosed disabilities.
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?
The Motley Fool
09 мая 2023 г. в 15:37
Axsome launched its first in-house developed drug last year -- the antidepressant Auvelity. In its first full quarter of commercialization, Auvelity reached more than 30,000 patients.
Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises
Zacks Investment Research
09 мая 2023 г. в 10:42
Axsome (AXSM) incurs a narrower-than-expected loss in 1Q23. Its revenues beat estimates and stock gains.
Axsome Therapeutics, Inc. (AXSM) Q1 2023 Earnings Call Transcript
Seeking Alpha
08 мая 2023 г. в 14:22
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2023 Earnings Conference Call May 8, 2023 8:00 AM ET Company Participants Mark Jacobson - Investor Relations Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer Lori Englebert - Executive Vice President, Commercial and Business Development Conference Call Participants Charles Duncan - Cantor Fitzgerald Marc Goodman - SVB Securities David Amsellem - Piper Sandler Joon Lee - Truist Securities Vikram Purohit - Morgan Stanley Yatin Suneja - Guggenheim Partners Joseph Thome - TD Cowen Graig Suvannavejh - Mizuho Securities Myles Minter - William Blair Matt Kaplan - Ladenburg Thalmann Boobalan Pachaiyappan - H.C. Wainwright Operator Hello and welcome to the Axsome Therapeutics First Quarter 2023 Financial Results Conference Call and Webcast.
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
08 мая 2023 г. в 09:54
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.03 per share a year ago.